Arrowhead (ARWR) Hits Record High Ahead of Expanded Plozasiran Approval

Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock surged to a five‑year peak as investor positioning intensified ahead of the anticipated sNDA filing for plozasiran.

Clinical Triumphs and Market Reaction

■Intraday price jumped 28%, reaching $95.49 – a level not seen since 2021.

■In Phase 3 trials, a 25 mg dose administered every three months cut triglyceride levels by 79% and 81%, versus a 27% reduction in the placebo arm.

■Acute pancreatitis incidence among patients with severe hypertriglyceridemia fell by 78%.

sNDA Strategy and Expanded Indication

■Plozasiran, marketed as Redemplo, received FDA approval in Nov 2025 for the rare genetic disorder Familial Chylomicronemia Syndrome (FCS).

■The company aims to submit a supplemental NDA for the drug’s use in severe hypertriglyceridemia by year‑end.

■Approvals in Europe, Australia, and Canada for FCS further cement its global market footprint.

Financial Impact and Investor Timeline

■Q3 2026 earnings will be released after market close on Aug 4, followed by a conference call.

■Detailed Phase 3 results will be presented at ESC 2026 on Aug 30.

■Investors are building positions, betting that the sNDA approval and label expansion will sustain the stock’s upside.

Markets are treating plozasiran’s robust trial data and the prospect of an expanded label as a catalyst. Even in a risk‑off climate, biotech firms focused on rare diseases like ARWR attract liquidity flows. Nonetheless, the regulatory risk of the sNDA process and potential competitive pressures must be factored in, as they could elevate stock volatility. In the short term, a 25‑30% upside is plausible, while a successful label expansion could diversify revenue streams and underpin a more durable valuation over the longer horizon.